DOI : 10.1055/s-00000094

Zeitschrift für Gastroenterologie

Ausgabe 08 · Volume 59 · August 2021 DOI: 10.1055/s-011-51669


54. Jahrestagung & 31. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie – ÖGGH (Hybrid Veranstaltung)
Linz, 09.-11.09.2021

Kongresspräsident: Prim. Univ.-Prof. Dr. Michael Gschwantler Kongresssekretäre: Univ.-Prof. Dr. Alexander R. Moschen PhD Assoz.Prof. Priv.-Doz. Dr. Thomas Reiberger OA Dr. Alexander Ziachehabi Fortbildungskurs: Univ.-Prof. Dr. Peter Ferenci Univ.-Prof. Dr. Heinz Zoller Prim. Univ.-Prof. Dr. Michael Gschwantler
Abstracts (HTML) Abstracts (PDF) Autorenliste
P01
Ecker, D; Fuchssteiner, H; Gregus, M; Piringer, P; Wewalka, F; Schöfl, R; Kienbauer, M: Ustekinumab bei Colitis ulcerosa - Real-world experience
P02
Mayr, L; Schwärzler, J; Grabherr, F; Niederreiter, L; Philipp, M; Enrich, B; Oberhuber, G; Sprung, S; Ran, Q; Koch, R; Effenberger, M; Kaneider, NC; Wieser, V; Aden, K; Rosenstiel, P; Blumberg, RS; Kaser, A; Tilg, H; Adolph, TE: Polyunsaturated fatty acids in a Western diet trigger TLR2-dependent Crohn’s-like enteritis in mice
P03
Kutschera, M; Primas, C; Reinisch, S; Novacek, G; Kim, S; Lee, S; Lee, J; Mould, D; Reinisch, W: Initial Clearance of Infliximab is a predictor for long-time mucosal healing and biomarker response
P04
Kutschera, M; Primas, C; Reinisch, S; Novacek, G; Kim, S; Lee, S; Lee, J; Mould, D; Reinisch, W: Initial Clearance of Infliximab is a predictor for the time of formation of anti-drug antibodies.
P05
Koch, R; Feagan, BC; Loftus, EV; Danese, S; Vermeire, S; Sandborn, WJ; Ritter, T; Mehta, R; Seidler, U; Seibold, F; Beales, I; Kim, H; McNally, J; Yun, C; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G; Hibi, T; Peyrin-Biroulet, L: Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study
P06
Koch, R; Peyrin-Biroulet, L; Loftus, EV; Danese, S; Vermeire, S; Sandborn, WJ; Fogel, R; Nijhawan, S; Kempinski, R; Filip, R; Hospodarskyy, I; McNally, J; Yun, C; Zhao, S; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G; Hibi, T; Feagan, BG: Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study
P07
Novacek, G; Bokemeyer, B; Kaiser, C; Primas, C; Biedermann, L; Seibold, F; Tappe, U; Bettenworth, D; Graw, J; Hartmann, P; Plachta-Danielzik, S; Gröchenig, H; Dinkhauser, P; Mayer, A; Koch, R; Högenauer, C; Tillinger, W; Apostol, S; Reicht, G; Feichtenschlager, T; Schultz, C: Potential of managed care programmes for patients with inflammatory bowel diseases - results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASEIBDstudy)
P08
Maier, H; Hartl, C; Primas, C; Sonneck, K; Itzlinger-Monshi, B; Kienbauer, M; Geroldinger-Simic, M; Högenauer, C; Rainer, B; Reinisch, S; Reinisch, W; Kazemi-Shirazi, L; Novacek, G: Impact of skin examination prior to initiation of treatment with biologics in Inflammatory Bowel Disease patients: preliminary data
P09
Pimingstorfer, P; Zollner, A; Watschinger, C; Moschen, AR: Safety and efficacy of the mRNA-1273 SARS-CoV-2 vaccine in a cohort of patients with inflammatory bowel disease
P10
Blesl, A; Gröchenig, H; Novacek, G; Primas, C; Kutschera, M; Illiasch, C; Hennlich, B; Steiner, P; Moschen, A; Koch, R; Tillinger, W; Haas, T; Reicht, G; Mayer, A; Ludwiczek, O; Miehsler, W; Steidl, K; Binder, L; Kump, P; Högenauer, C: Corticosteroid therapy of flares in ulcerative colitis is less effective in patients with prior biologic therapy
P11
Watschinger, C; Macheiner, S; Kozsar, A; Przysiecki, N; Gerner, RR; Moschen, AR: A risk variant within the ‘interferon induced with helicase C domain 1ʹ (IFIH1) gene render epithelial cells susceptible for microbial stimuli
P12
Piribauer, M; Bergmeister, P; Frick, C; Johannes, J; Mutschlechner, B; Benda, M; Grabher, C; Fraunberger, P; Ulmer, H; Hartmann, B; Peters, P; Winder, T: Antibody response to bnt162b2 mRNA vaccine in patients with IBD or chronic liver disease